North America Intravenous Iron Drugs Market Size & Outlook

The intravenous iron drugs market in North America is expected to reach a projected revenue of US$ 2,606.3 million by 2030. A compound annual growth rate of 7.9% is expected of North America intravenous iron drugs market from 2024 to 2030.
Revenue, 2023 (US$M)
$1,534.5
Forecast, 2030 (US$M)
$2,606.3
CAGR, 2024 - 2030
7.9%
Report Coverage
North America

North America intravenous iron drugs market, 2018-2030 (US$M)

North

North America intravenous iron drugs market highlights

  • The North America intravenous iron drugs market generated a revenue of USD 1,534.5 million in 2023.
  • The market is expected to grow at a CAGR of 7.9% from 2024 to 2030.
  • In terms of segment, ferric carboxymaltose was the largest revenue generating product in 2023.
  • Ferric Carboxymaltose is the most lucrative product segment registering the fastest growth during the forecast period.
  • Country-wise, Canada is expected to register the highest CAGR from 2024 to 2030.


North America data book summary

Market revenue in 2023USD 1,534.5 million
Market revenue in 2030USD 2,606.3 million
Growth rate7.9% (CAGR from 2023 to 2030)
Largest segmentFerric carboxymaltose
Fastest growing segmentFerric Carboxymaltose
Historical data covered2018 - 2022
Base year for estimation2023
Forecast period covered2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationIron Dextran, Iron Sucrose, Ferric Carboxymaltose
Key market players worldwideAbbVie Inc, Civitas Resources Inc Ordinary Shares, Daiichi Sankyo Co Ltd, Sanofi SA, CSL Ltd, COSMOS Pharmaceutical Corp, Zydus Lifesciences, Rockwell Medical Inc


Other key industry trends

  • In terms of revenue, North America region accounted for 50.7% of the global intravenous iron drugs market in 2023.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 819.2 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Intravenous Iron Drugs Market Scope

Intravenous iron drugs market segmentation & scope
Iron Dextran
Iron Sucrose
Ferric Carboxymaltose
Others
Chronic Kidney Disease
Inflammatory Bowel Disease
Cancer
Other Diseases

Intravenous Iron Drugs Market Companies

Name Profile # Employees HQ Website

North America intravenous iron drugs market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to intravenous iron drugs market will help companies and investors design strategic landscapes.


Ferric carboxymaltose was the largest segment with a revenue share of 44.99% in 2023. Horizon Databook has segmented the North America intravenous iron drugs market based on iron dextran, iron sucrose, ferric carboxymaltose covering the revenue growth of each sub-segment from 2018 to 2030.


In 2022, North America held a substantial share of the Intravenous (IV) iron drugs market, primarily due to the increasing approvals and launch of new IV drugs in the U.S. For instance, in December 2021, American Regent, Inc. and Daiichi Sankyo, Inc. disclosed that the U.S. FDA granted approval for Injective for pediatric patients with Iron Deficiency Anemia (IDA) who are insensitive to oral iron or who have exhibited an inadequate response to receiving oral iron.

These patients must be at least a year old. The suggested dosage for patients weighing below 50 kg is two intravenous doses of Injective 15 mg/kg body weight at least 7 days apart for each course. North America held a dominant share of the market, which can be attributed to increasing prevalence of cancer, Chronic Kidney Disease (CKD), and gastrointestinal disorders in the region.

For instance, according to the International Agency for Research on Cancer (IARC), over 20.7 million new cancer cases are expected to be diagnosed in 2023. Furthermore, increasing awareness about women’s health and rising prevalence of celiac diseases are also some of the other factors driving the regional market growth.

Reasons to subscribe to North America intravenous iron drugs market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of North America intravenous iron drugs market databook

  • Our clientele includes a mix of intravenous iron drugs market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the North America intravenous iron drugs market , including forecasts for subscribers. This continent databook contains high-level insights into North America intravenous iron drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

North America intravenous iron drugs market size, by country, 2018-2030 (US$M)

North America Intravenous Iron Drugs Market Outlook Share, 2023 & 2030 (US$M)

North America intravenous iron drugs market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more